Policy & Regulation
Foundation Medicine to Present Data Supporting Use of Genomic Profiling at 2018 American Association for Cancer Research meeting
13 April 2018 - - Cambridge, Massachusetts-based molecular information company Foundation Medicine, Inc. (NASDAQ: FMI) will present new findings at the American Association for Cancer Research (AACR) annual meeting being held April 14-18, 2018 at McCormick Place in Chicago, Illinois, the company said.
The data support the use of both tissue- and blood-based comprehensive genomic profiling to advance personalized cancer care and inform the use of targeted and immunotherapy treatment approaches.
Presentations span several of Foundation Medicine's suite of molecular information products including its recently FDA approved assay, FoundationOne CDx, as well as FoundationOne, FoundationACT, and the company's novel blood-based assay to measure tumor mutational burden.
In the area of immunotherapy, new data will be presented highlighting the use of Foundation Medicine's bTMB assay, which is currently being utilized in a global clinical trial setting to investigate bTMB as a non-invasive biomarker of response to first-line atezolizumab in advanced non-small cell lung cancer (NSCLC) patients as part of Roche/Genentech's prospective, randomized Phase III Blood First Assay Screening Trial (BFAST).
Data generated utilizing the FoundationACT liquid biopsy assay will be presented, which supports its potential utility in predicting clinical outcomes.
Clinical validation data for FoundationOne CDx will also be presented, demonstrating high concordance with multiple FDA-approved companion diagnostics, as well as other assays, including another CLIA-validated next generation sequencing assay and other single marker assays, currently used to identify targeted therapies in patients with NSCLC, melanoma, colorectal cancer, ovarian cancer, and breast cancer.
Other studies include those that identify novel biomarkers of targeted therapy treatment response, such as novel PTEN alterations in metastatic triple negative breast cancer (mTNBC), or genomic loss of heterozygosity in non-BRCA positive ovarian cancer patients.
Foundation Medicine offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.
Its molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers, and drug developers to help advance the science of molecular medicine in cancer.


Related Headlines